Discontinued Operations - Schedule of discontinued operation in operations statement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Discontinued operation operating expense
Intangible asset impairment loss	$ 2,277,921
Gain on sale of discontinued operations	(1,467,451)
Unrealized gain (loss) on available-for-sale securities	123,019	$ (1,701,443)
Net loss from discontinued operations before income taxes	(5,005,518)	(5,560,130)
Income tax expense from discontinued operations	(65,189)	3,073,000
Net loss from discontinued operations, net of tax benefit	(5,070,707)	(2,487,130)
Elusys Therapeutics business unit
Discontinued Operations
Revenue	6,699,200	6,012,993
Discontinued operation operating expense
Cost of revenues	2,163,723	6,319,723
Research and development	2,549,959	3,237,905
Selling, general and administrative	1,346,565	1,000,333
Amortization of intangible asset	1,091,250	1,030,625
Goodwill impairment loss	3,873,079
Intangible asset impairment loss	2,277,921
Change in fair value of contingent consideration	(107,355)	(109,500)
Total operating expenses	13,195,142	11,479,086
Loss from operations	(6,495,942)	(5,466,093)
Gain on sale of discontinued operations	(1,467,451)
Other expense, net	(22,973)	94,037
Total non-operating (loss) income	(1,490,424)	94,037
Net loss from discontinued operations before income taxes	(5,005,518)	(5,560,130)
Income tax expense from discontinued operations	(65,189)	3,073,000
Net loss from discontinued operations, net of tax benefit	$ (5,070,707)	$ (2,487,130)